Effective elimination of cancer stem cells by a novel drug combination strategy

Area of Science:

• Oncology
• Cancer Metabolism
• Glioblastoma Research

Background:

• Cancer stem cells (CSCs) are implicated in therapeutic resistance and tumor recurrence.
• Glioblastoma stem cells (GSCs) exhibit distinct metabolic profiles, including high glycolytic activity.
• Standard chemotherapies like carmustine and temozolomide (TMZ) show limited efficacy against GSCs.

Purpose of the Study:

• To investigate the metabolic vulnerabilities of glioblastoma stem cells (GSCs).
• To evaluate the efficacy of a glycolytic inhibitor, 3-bromo-2-oxopropionate-1-propyl ester (3-BrOP), against GSCs.
• To explore synergistic therapeutic strategies combining 3-BrOP with standard chemotherapies.

Main Methods:

• Metabolic characterization of GSCs, including mitochondrial respiration and glycolytic activity assays.
• Assessment of GSC sensitivity to 3-BrOP and standard chemotherapies (carmustine, TMZ) under normoxic and hypoxic conditions.
• Evaluation of drug combination effects on GSC viability, ATP levels, DNA repair, sphere formation, and tumor growth in vivo.

Main Results:

• GSCs demonstrated high glycolytic activity and resistance to carmustine and TMZ.
• 3-BrOP effectively inhibited GSC growth, particularly under hypoxia.
• Combination of 3-BrOP with carmustine, but not TMZ, exhibited synergistic effects, leading to ATP depletion and impaired DNA repair.
• This combination significantly reduced GSC sphere formation, tumor growth, and improved survival in mice.

Conclusions:

• Glioblastoma stem cells possess a highly glycolytic metabolism that can be targeted therapeutically.
• Combining the glycolytic inhibitor 3-BrOP with carmustine offers a promising synergistic strategy to overcome GSC drug resistance.
• Targeting cancer stem cell metabolism represents a viable approach to enhance glioblastoma treatment outcomes.